Analysts Are Bullish on Top Healthcare Stocks: Pliant Therapeutics (PLRX), Simulations Plus (SLP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pliant Therapeutics (PLRX – Research Report), Simulations Plus (SLP – Research Report) and Polynovo Limited (CALZF – Research Report) with bullish sentiments.

Pliant Therapeutics (PLRX)

In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Pliant Therapeutics, with a price target of $50.00. The company’s shares closed last Monday at $14.58.

According to TipRanks.com, Lebovitz is a 2-star analyst with an average return of 0.6% and a 50.3% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pliant Therapeutics with a $48.64 average price target.

See the top stocks recommended by analysts >>

Simulations Plus (SLP)

In a report released yesterday, David Larsen from BTIG maintained a Buy rating on Simulations Plus, with a price target of $55.00. The company’s shares closed last Monday at $40.68.

According to TipRanks.com, Larsen is ranked 0 out of 5 stars with an average return of -9.8% and a 31.4% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Privia Health Group, P3 Health Partners, and Health Catalyst.

Simulations Plus has an analyst consensus of Strong Buy, with a price target consensus of $61.00.

Polynovo Limited (CALZF)

Macquarie analyst Rachael Harwood maintained a Buy rating on Polynovo Limited today and set a price target of A$2.70. The company’s shares closed last Tuesday at $1.06.

According to TipRanks.com, Harwood is ranked #6717 out of 8560 analysts.

Currently, the analyst consensus on Polynovo Limited is a Moderate Buy with an average price target of $1.24.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PLRX:

• Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
• Pliant Therapeutics appoints Kuo as Chief Development Officer
• Pliant Therapeutics to Participate in Upcoming Investor Conferences
• Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
• Pliant Therapeutics management to meet with Oppenheimer